UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 29, 2018
TREVENA, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-36193 |
|
26-1469215 |
|
(Commission
|
|
(IRS Employer
|
955 Chesterbrook Boulevard, Suite 200
Chesterbrook, PA 19087
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (610) 354-8840
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) On February 2, 2018, Trevena, Inc. (“Trevena” or the “Company”) announced the appointment of Carrie L. Bourdow, 55, to the position of Executive Vice President and Chief Operating Officer, effective immediately. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
(e) In connection with this appointment, Ms. Bourdow’s annual base salary was increased to $385,000 and her target cash incentive opportunity was increased to 45 percent of her annual base salary.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit
|
|
Exhibit Description |
|
|
|
|
|
99.1 |
|
Press release dated February 2, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: February 2, 2018 |
TREVENA, INC. |
|
|
|
|
|
|
|
By: |
/s/ John M. Limongelli |
|
|
|
John M. Limongelli |
|
|
|
Sr. Vice President, General Counsel & Chief
|
Trevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating Officer
CHESTERBROOK, PA, February 2, 2018 - Trevena, Inc. (NASDAQ: TRVN) today announced the promotion of Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to Executive Vice President and Chief Operating Officer, effective immediately. Ms. Bourdow brings to this newly created position over 25 years of experience at large and small commercial biopharmaceutical companies.
“Since joining Trevena, Carrie has taken on increasing leadership across the organization as we have advanced OLINVO™ towards its potential approval later this year,” said Maxine Gowen, Ph.D., chief executive officer. “This new role recognizes Carrie’s many contributions to Trevena, and reflects our belief in her leadership for the future success of the Company.”
Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015. Prior to joining Trevena, she was vice president of marketing, reimbursement, and operations at Cubist Pharmaceuticals, Inc., from 2013 to 2015, where she had responsibility for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to that, she served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across several therapeutic areas. Since June 2017, Ms. Bourdow has served on the board of Nabriva Therapeutics plc., a publicly traded biopharmaceutical company
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO TM (oliceridine) Injection for the management of moderate-to-severe acute pain. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including for acute migraine, neuropathic pain, and other indications.
Contacts
Investors
:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
jviolin@trevena.com
Media
:
Public Relations
PR@trevena.com
###